Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Table 4

Comparison of changes in the clinical and biochemical parameters during the study period between the intervention and control groups across glibenclamide, metformin, and metformin + glibenclamide treatment subgroups.

	Glibenclamide			Metformin			Glibenclamide + metformin
	Control group	Intervention group	P value	Control group	Intervention group	P value	Control group	Intervention group	P value
Systolic blood pressure	0.01; (−5.00, 1.25)	−10.00; (−16.25, −3.75)	0.016*	0.01; (−1.25, 10.00)	−10.00; (−10.00, 0.01)	0.043*	0.01; (0.01, 5.00)	−10.00; (−12.50, −2.50)	0.003*
Fasting glucose	13.0; (4.50, 31.50)	−25.00; (−84.50, −5.75)	<0.0001*	2.00; (−3.50, 12.00)	−25.00; (−32.00, −10.00)	0.005*	7.00; (1.00, 22.00)	−32.00; (−47.50, −22.50)	<0.0001*
Insulin	0.06; (−3.85, 5.39)	−4.42; (−7.85, −2.31)	0.042*	0.73; (0.06, 1.05)	−1.32; (−3.39, −0.04)	0.088	0.37; (0.32, 0.95)	−7.71; (−9.31, −1.96)	0.002*
HbA1c	−0.15; (−1.04, 0.200)	−1.55; (−2.22, −0.97)	0.031*	−0.15; (−0.70, 0.22)	−0.60; (−2.00, −0.02)	0.133	0.05; (−0.10, 0.50)	−1.10; (−2.05, −0.90)	<0.0001*
HOMA-IR	0.17; (−1.53, 3.69)	−2.12; (−5.07, −1.16)	0.022*	0.27; (0.15, 0.65)	−0.86; (−1.25, −0.31)	0.043*	0.24; (−0.26, 0.56)	−2.86; (−5.22, −1.12)	<0.0001*
HDL-cholesterol	−1.65; (−5.77, 1.40)	6.25; (2.82, 11.26)	0.003*	0.10; (−4.07, 2.95)	4.60; (1.40, 12.05)	0.043*	−2.80; (−4.70, 0.60)	6.10; (0.35, 11.20)	<0.0001*
LDL-cholesterol	8.0; (5.50, 18.0)	−17.50; (−35.75, −10.50)	0.005*	4.50; (−1.25, 20.75)	−7.0; (−70.00, 2.00)	0.007*	1.00; (−2.00, 4.00)	−9.00; (−32.00, 1.50)	0.030*

Data is presented as medians (Interquartile ranges). ^∗𝑃<0.05 versus control group. HOMA-IR: homeostasis model of assessment for insulin resistance; HbA1c: Hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein.